MOUD Buprenorphine Sublocade denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for moud buprenorphine sublocade are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Quantity Limits to Sublocade — and How to Appeal Them

A quantity-limit denial for Sublocade means UitedHealthcare's plan restricts the frequency or supply of extended-release injectable buprenorphine beyond what your prescriber ordered. Because Sublocade is a once-monthly injection, a quantity-limit denial typically reflects a disagreement about the number of injections approved per authorization period rather than per-dose strength. This is a reviewable benefit determination.

## Why Quantity-Limit Denials Are Appealable

Quantity limits are a coverage design decision, but they must align with the FDA-approved dosing regimen in the prescribing label. If UHC's quantity limit is inconsistent with the FDA-labeled administration schedule for this product, that is a substantive appeal ground. Additionally, if UHC imposes more restrictive quantity controls on OUD medications than on chronic-condition medications requiring comparable administration frequency, that disparity may constitute a parity violation under MHPAEA.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): Submit a written internal appeal within the deadline on your denial letter. The prescriber should document why the prescribed quantity matches the FDA-approved administration schedule.
• Formulary / quantity-limit exception: Separately, request a quantity-limit exception through the standard PA exception pathway — it may resolve faster than a formal appeal.
• External review: After exhausting internal review, you have up to approximately four months from the internal denial notice to request independent external review under ACA §2719.
• Expedited review: Available if the quantity limit creates an urgent gap in treatment.

## Concrete Appeal Steps

1. Obtain the denial letter and confirm the exact limit being applied (e.g., injections per calendar year or per authorization period). 2. Download the FDA prescribing label for Sublocade from Drugs@FDA and identify the labeled administration schedule. 3. Pull UHC's published quantity-limit policy for Sublocade. 4. Have the prescriber draft a letter explaining that the ordered quantity aligns with the FDA-approved administration schedule and is medically necessary for continuous OUD treatment. 5. File the appeal with the documentation package below.

## Documentation to Gather

• FDA prescribing label: From Drugs@FDA, showing the labeled administration schedule for Sublocade — the primary basis for arguing the quantity limit is inconsistent with approved use.
• Diagnosis confirmation: DSM-5 moderate-to-severe OUD diagnosis.
• Prescriber letter: Explaining the clinical necessity of uninterrupted monthly administration and documenting the treatment plan duration.
• Treatment continuity rationale: If the patient has been on Sublocade, document the clinical response and risk of treatment interruption.
• Criteria-mapping table: UHC's quantity-limit criteria in one column; the FDA label and chart evidence in the other.

## Criteria-Mapping Structure

For quantity-limit appeals, the table should include: (1) UHC's stated limit, (2) the FDA-approved frequency from the prescribing label, (3) the prescriber's ordered quantity, and (4) the clinical rationale for that quantity. Where the plan's limit is less than the FDA-labeled frequency, that gap is the core of your appeal argument.